NCT04590508View on ClinicalTrials.gov

A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

August 22, 2024

Study Completion Date

July 30, 2025

Conditions
Crohn Disease
Interventions
DRUG

Xanthohumol

The xanthohumol supplement will be administered in a capsule and taken orally.

OTHER

Placebo

The placebo will be administered in a capsule and taken orally.

Trial Locations (1)

97201

National University of Natural Medicine, Portland

All Listed Sponsors
collaborator

Oregon State University

OTHER

collaborator

Pacific Northwest National Laboratory

FED

lead

National University of Natural Medicine

OTHER